| Objective:To evaluate of leosimendan treatment the curative effect of patients with decompensated heart failure.To clear levosimendan and milrinone for patients with heart failure of heart function improved, NT-pro BNP, LVEF, SV and CVP.Methods:Patients were recruited into this single center, randomized, positive-controlled and parallel-group study to receive levosimendan or milrinone treatment.All patients in criteria based on drug treatment of the acute heart failure, combined the levosimendan and milrinone.In the levosimendan group, an initial loading dose of levosimendan of 10 μg/Kg,it was infused over 10 minutes, followed a continuous infusion of 0.1μg/Kg/min for 24hours; In the control group, an initial loading dose of milrinone of 25μg/Kg, it was infused over 10 minutes, followed a continuous infusion of 0.25μg/Kg/min for 24 hours.By measuring NT-pro BNP, LVEF, SV, CVP and evaluate the efficacy of systemic clinical symptoms to comprehensive evaluation of drugs.Results:Patients were enrolled in the test group of 40 patients and the control group of 40 cases.24h after treatment experimental group and a control group of left ventricular ejection fraction(LVEF) increased the mean was 10.5% and 4.5%, Compared to the two groups(P> 0.05).24 h after treatment experimental group and a control group of stroke volume(SV) increased the mean was 16 and 5 milliliter, Compared to the twogroups(P<0.05).24 h after treatment experimental group and a control group of N-terminal brain natriuretic peptide precursor(NT-pro BNP) declined 66.01% and 57.14%(P<0.05).Central venous pressure in the test group after treatment 24h(CVP) than the control group decreased significantly(P< 0.05).Dyspnea and general clinical condition of the patient test group than the control group improved significantly.Experimental group was not the incidence of adverse reactions.Adverse reactions of the control group were hypotension and ventricular premature beats.Conclusion:Examination in patients with clinical symptoms improved significantly, the mean LVEF and SV rise were higher than control group, NT-pro BNP and CVP was droped down than the control group.Safety and tolerability was excellent.Compared with the control drug milrinone.It is showed that leosimendan is better of treatment acute decompensated heart failure. |
PDF Full Text Request